Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taxoprexin in metastatic uveal melanoma
NCT00244816Phase 2Completed
- Sponsor
- American Regent, Inc.
- Start
- Oct 2005
- Primary completion
- Jun 2008
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel docosahexaenoic acid in Uveal melanoma (UM), sponsored by American Regent, Inc. Primary endpoints: Objective Response Rate at 24 weeks, Duration of Response at 24 months and 1 more. Started Oct 2005; status: completed.
02
Drugs
paclitaxel docosahexaenoic acid
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT00244816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00244816.